Comparative clinical significance and biological roles of PFKFB family members in oral squamous cell carcinoma

Table 3 The association of PFKFB3 expression with prognosis in oral cancer patients stratified by different clinicopathological features

PFKFB3	ROC	OS			PFI			DFI			DSS
PFKFB3	ROC	No	AHR	p	No	AHR	p	No	AHR	p	No	AHR	p
Sex
Female	Low	9	1		74	1		25	1		69	1
Female	High	74	1.48	0.707^a	9	2.12	0.149^a	8	2.09	0.377^a	9	2.65	0.145^a
Male	Low	16	1		166	1		38	1		156	1
Male	High	167	2.01	0.240^a	17	1.78	0.079^a	6	1.81	0.457^a	19	2.40	0.009^a
Age
< = 60	Low	9	1		105	1		20	1		101	1
< = 60	High	104	2.27	0.423^a	8	1.42	0.468^a	5	0.00	0.979^a	9	1.85	0.211^a
> 60	Low	16	1		135	1		43	1		124	1
> 60	High	137	1.85	0.307^a	18	2.14	0.026^a	9	3.13	0.049^a	19	2.76	0.008^a
Cell differentiation
Well	Low	6	1		37	1		14	1		34	1
Well	High	32	558328.67	0.980^b	1	29.22	0.017^b	4	1.09	0.950^b	2	10.79	0.062^b
Moderate + Poor	Low	19	1		203	1		49	1		191	1
Moderate + Poor	High	209	1.46	0.463^b	25	1.71	0.060^b	10	2.27	0.178^b	26	2.22	0.009^b
N classification
N0	Low	13	1		107	1		47	1		99	1
N0	High	105	1.45	0.624^e	11	2.01	0.130^e	12	1.10	0.896^e	13	2.72	0.060^e
N1,N2,N3	Low	12	1		133	1		16	1		126	1
N1,N2,N3	High	136	1.96	0.352^e	15	1.76	0.107^e	2	7.88	0.042^e	15	2.12	0.040^e
T classification
T1 + T2	Low	17	1		99	1		52	1		97	1
T1 + T2	High	89	2.16	0.300^d	7	1.89	0.303^d	8	1.66	0.522^d	7	1.66	0.631^d
T3 + T4	Low	8	1		141	1		11	1		128	1
T3 + T4	High	152	1.33	0.696^d	19	1.86	0.046^d	6	7.82	0.114^d	21	2.38	0.006^d
AJCC pathological stage
I + II	Low	10	1		54	1		39	1		52	1
I + II	High	47	2.32	0.425	3	6.31	0.019^c	7	0.88	0.909^c	4	6.86	0.105^c
III + VI	Low	15	1		186	1		24	1		173	1
III + VI	High	194	1.80	0.317^c	23	1.72	0.068^c	7	3.49	0.077^c	24	2.35	0.006^c

OS overall survival, PFI progression-free interval survival, DFI disease-specific survival, DSS disease-specific survival, ROC receiver operating characteristic curve, AJCC American Joint Committee on Cancer, CI confidence interval, AHR adjusted hazard ratio
^aAdjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs stage I + II)
^bAdjusted for AJCC pathological stage (stage III + IV vs stage I + II)
^cAdjusted for cell differentiation (moderate + poor vs. well)
^dAdjusted for cell differentiation (moderate + poor vs. well) and N classification (N1, N2 vs N0)
^eAdjusted for cell differentiation (moderate + poor vs. well) and T classification (T3, T4 vs T1 + T2)

ISSN: 1475-2867